19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

Key Takeaways Explain This Topic AI

Acute neuromuscular respiratory failure is characterized by primary ventilatory pump failure rather than gas-exchange impairment; bedside pulmonary mechanics follow the 'Rule of 20/30/40' (Vital Capacity < 20 mL/kg, NIF worse than -30 cmH2O, and MEP < 40 cmH2O) to dictate elective endotracheal intubation before the catastrophic onset of late hypoxemia or hypercapnia.

In Myasthenia Gravis Crisis, therapeutic plasma exchange (PLEX) or IVIG is first-line; oral acetylcholinesterase inhibitors (pyridostigmine) must be immediately discontinued upon intubation to prevent excessive airway secretions and cholinergic crisis, and exacerbating medications (aminoglycosides, fluoroquinolones, beta-blockers, magnesium sulfate) must be strictly avoided.

Guillain-Barré Syndrome (GBS) presents with progressive ascending flaccid paralysis and autonomic instability, characterized by CSF albuminocytologic dissociation; treatment is IVIG or PLEX, while systemic corticosteroids are ineffective and contraindicated, and succinylcholine carries a life-threatening risk of hyperkalemia.

ICU-acquired weakness distinguishes Critical Illness Myopathy (CIM: preserved sensation, low CMAP with normal SNAP, loss of thick myosin filaments) from Critical Illness Polyneuropathy (CIP: sensorimotor axonal loss, reduced CMAP and SNAP, normal CK, slower recovery); risk is mitigated by minimizing neuromuscular blockade and systemic steroids.

The 2023 AAN/AAP/CNS/SCCM brain death determination guidelines mandate establishing an irreversible etiology, normothermia (>= 36.0°C), hemodynamic stability (SBP >= 100 mmHg), complete absence of all brainstem reflexes, and a positive apnea test (PaCO2 >= 60 mmHg and >= 20 mmHg rise above baseline with arterial pH < 7.30); spinal reflexes and the Lazarus sign do not preclude brain death.

Last updated: October 2026

Pathophysiology of Neuromuscular Respiratory Failure & Bedside Pulmonary Mechanics

Neuromuscular respiratory failure represents a distinct clinical entity in the intensive care unit. Unlike primary lung parenchymal disorders (e.g., ARDS, acute pneumonia, or cardiogenic pulmonary edema) that present primarily with severe gas-exchange impairment, acute neuromuscular disorders cause primary ventilatory pump failure : Neuromuscular Failure Hierarchy:

• [1. Inspiratory Pump Exhaustion] --> Microatelectasis --> Decreased FRC --> Hypoxemia (Late)
• [2. Expiratory Pump Failure] --> Ineffective Cough --> Mucus Plugging --> Atelectasis/Aspiration
• [3. Bulbar Muscle Dysfunction] --> Loss of Airway Protection --> Secretion Pooling --> Asphyxia

Inspiratory Muscle Failure : Progressive weakness of the diaphragm (innervated by C 3 − C 5 C_3-C_5 C 3 ​ − C 5 ​ phrenic nerves) and external intercostal muscles leads to shallow tidal breathing, generalized microatelectasis, loss of lung compliance, and a profound reduction in Functional Residual Capacity (FRC).

Expiratory Muscle Weakness : Paralysis of the abdominal wall musculature and internal intercostal muscles impairs the generation of positive intrathoracic pressures required for an effective cough, resulting in retained tracheobronchial secretions, progressive mucus plugging, and secondary aspiration pneumonia.

Bulbar Muscle Dysfunction : Cranial nerve palsies (CN IX, X, XII) cause weakness of the pharyngeal, laryngeal, and tongue musculature, leading to loss of airway patency, pooling of oral secretions, and acute upper airway obstruction.

Bedside Pulmonary Mechanics: The "Rule of 20/30/40"

Clinical examination parameters (e.g., tachypnea, staccato speech, paradoxical abdominal breathing) often precede frank ventilatory failure. Serial bedside spirometry and manometer measurements provide quantitative, objective triggers for elective endotracheal intubation:

Bedside Parameter Normal Value Critical Threshold for Impending Intubation Clinical Significance

Vital Capacity (VC) 60 − 70 mL/kg 60-70\text{ mL/kg} 60 − 70 mL/kg < 20 mL/kg < 20\text{ mL/kg} < 20 mL/kg ( < 10 − 15 mL/kg < 10-15\text{ mL/kg} < 10 − 15 mL/kg is critical) Reflects total respiratory muscular reserve; values < 20 mL/kg < 20\text{ mL/kg} < 20 mL/kg signal severe diaphragmatic exhaustion

Negative Inspiratory Force (NIF) − 70 to − 100 cmH 2 O -70\text{ to } -100\text{ cmH}_2\text{O} − 70 to − 100 cmH 2 ​ O Worse than − 30 cmH 2 O -30\text{ cmH}_2\text{O} − 30 cmH 2 ​ O (e.g., − 20 to 0 -20\text{ to } 0 − 20 to 0 ) Measures maximum isometric inspiratory strength; values worse than − 30 cmH 2 O -30\text{ cmH}_2\text{O} − 30 cmH 2 ​ O indicate severe diaphragmatic fatigue

Maximum Expiratory Pressure (MEP) > 100 cmH 2 O > 100\text{ cmH}_2\text{O} > 100 cmH 2 ​ O < 40 cmH 2 O < 40\text{ cmH}_2\text{O} < 40 cmH 2 ​ O Measures abdominal and expiratory strength; values < 40 cmH 2 O < 40\text{ cmH}_2\text{O} < 40 cmH 2 ​ O indicate inability to cough and clear airway secretions

Important

The Arterial Blood Gas and Pulse Oximetry Trap :

In acute neuromuscular respiratory failure, gas exchange remains completely normal until the patient reaches end-stage diaphragmatic exhaustion. Arterial oxygen saturation ( SpO 2 \text{SpO}_2 SpO 2 ​ ), PaO 2 \text{PaO}_2 PaO 2 ​ , and PaCO 2 \text{PaCO}_2 PaCO 2 ​ frequently remain within normal limits despite severely depressed vital capacity. Relying on the onset of hypoxemia or hypercapnia to trigger intubation results in sudden, catastrophic respiratory arrest and dangerous emergency airway management.

Non-Invasive Ventilation (NIV) in Neuromuscular Crises

Non-invasive positive-pressure ventilation (NIV) has a limited and controversial role in acute neuromuscular crises. While NIV can be considered as a temporary bridge in mild, slowly evolving weakness with preserved bulbar function, it carries a failure rate exceeding 75 % 75\% 75% in patients with acute myasthenic crisis or rapidly progressive Guillain-Barré syndrome. Severe bulbar weakness, copious pooled secretions, impaired swallowing, or facial diplegia represent strict contraindications to NIV. When bedside parameters cross the 20/30/40 threshold, early elective endotracheal intubation is the standard of care.

Myasthenia Gravis Crisis

Myasthenic crisis is defined as an acute, life-threatening exacerbation of myasthenia gravis characterized by respiratory muscle weakness requiring mechanical ventilation or non-invasive ventilatory support. It occurs in approximately 15 − 20 % 15-20\% 15 − 20% of myasthenic patients during their lifetime.

Pathophysiology and Autoantibodies

Myasthenia gravis is an antibody-mediated autoimmune disease affecting the postsynaptic neuromuscular junction:

Anti-Acetylcholine Receptor Antibodies (AChR-Ab) : Present in ≈ 85 % \approx 85\% ≈ 85% of generalized myasthenia. Antibodies induce complement-mediated destruction of post-junctional folds, accelerate endocytosis and degradation of ACh receptors, and competitively block acetylcholine binding.

Anti-Muscle-Specific Kinase Antibodies (MuSK-Ab) : Present in 5 − 10 % 5-10\% 5 − 10% of patients (predominantly AChR-negative females). Characterized by severe, selective involvement of bulbar, facial, and neck extensor muscles, often presenting with early, acute respiratory failure. MuSK-positive disease responds poorly to acetylcholinesterase inhibitors.

Anti-LRP4 and Agrin Antibodies : Implicated in a small fraction of double-seronegative myasthenia.

Precipitants of Myasthenic Crisis

Systemic Infections : The most frequent trigger ( > 50 % > 50\% > 50% of cases), especially bacterial pneumonia, viral upper respiratory tract infections, and urinary tract sepsis.

Surgical Interventions : General anesthesia, postoperative pain, and stress (including thymectomy).

Rapid Changes in Immunosuppression : Abrupt reduction or tapering of oral corticosteroids, azathioprine, or mycophenolate mofetil.

Corticosteroid-Induced Paradoxical Flare ("Steroid Dip") : Initiating high-dose systemic corticosteroids without concurrent PLEX or IVIG can trigger a transient, severe worsening of myasthenic weakness in 30 − 40 % 30-40\% 30 − 40% of patients within the first 7 − 10 days 7-10\text{ days} 7 − 10 days .

Electrolyte Derangements : Severe hypokalemia, hypophosphatemia, and hypomagnesemia.

Immune Checkpoint Inhibitors (ICIs) : Agents targeting PD-1 (pembrolizumab, nivolumab) or CTLA-4 (ipilimumab) can unleash a fulminant, hyperacute autoimmune triad consisting of severe myasthenia gravis, necrotizing autoimmune myocarditis, and diffuse myositis, carrying a mortality rate exceeding 30 % 30\% 30% .

Medications Strictly Contraindicated in Myasthenia Gravis

Numerous pharmacological agents compromise neuromuscular junction transmission and can precipitate or worsen a myasthenic crisis: Medications to STRICTLY AVOID in Myasthenia Gravis:

• ├── Antibiotics: Aminoglycosides (gentamicin, tobramycin), Fluoroquinolones (ciprofloxacin, levofloxacin),
• │ Macrolides (azithromycin, erythromycin), Telithromycin, Polymyxins/Colistin
• ├── Cardiovascular: Beta-blockers (propranolol, labetalol, metoprolol), Calcium channel blockers,
• │ Antiarrhythmics (procainamide, quinidine, lidocaine)
• ├── Electrolytes: INTRAVENOUS MAGNESIUM SULFATE (potent presynaptic ACh release inhibitor)
• ├── Neuromuscular Blockers: Non-depolarizing NMBAs (extreme hypersensitivity/prolonged paralysis),
• │ Succinylcholine (resistance or unpredictable phase II block)
• └── Central Depressants: Benzodiazepines, high-dose opioids (blunts marginal respiratory drive)

Caution

Intravenous Magnesium Sulfate : Magnesium is a potent competitive inhibitor of calcium entry into the presynaptic motor nerve terminal, blocking acetylcholine release. Administering IV magnesium sulfate (e.g., for preeclampsia, asthma, or cardiac arrhythmias) in myasthenia gravis can induce immediate, complete neuromuscular collapse and fatal respiratory arrest.

Disease-Modifying Therapy in Crisis

Therapeutic Plasma Exchange (PLEX) : Considered the most rapid-acting disease-modifying modality. Standard dosing involves 5 plasma exchanges ( 3 − 4 L 3-4\text{ L} 3 − 4 L or 1 − 1.5 1-1.5 1 − 1.5 plasma volumes per exchange) over 10 − 14 days 10-14\text{ days} 10 − 14 days , replacing volume with 5 % 5\% 5% human albumin. PLEX removes pathogenic autoantibodies, circulating complement, and cytokines, with clinical improvement typically emerging within 24 − 48 hours 24-48\text{ hours} 24 − 48 hours . PLEX is preferred in MuSK-positive crisis and in patients with refractory disease.

Intravenous Immunoglobulin (IVIG) : Administered at a total dose of 2 g/kg 2\text{ g/kg} 2 g/kg divided over 2 to 5 days 2\text{ to }5\text{ days} 2 to 5 days ( 0.4 g/kg/day × 5 days 0.4\text{ g/kg/day} \times 5\text{ days} 0.4 g/kg/day × 5 days or 1 g/kg/day × 2 days 1\text{ g/kg/day} \times 2\text{ days} 1 g/kg/day × 2 days ). IVIG neutralizes autoantibodies, accelerates pathogenic IgG clearance, and downregulates Fc receptors. Large randomized controlled trials show equivalent overall efficacy between PLEX and IVIG.

The Golden Rule: Hold Acetylcholinesterase Inhibitors During Intubation

Warning

Discontinue Pyridostigmine Upon Endotracheal Intubation :

When a myasthenic crisis necessitates mechanical ventilation, oral pyridostigmine must be immediately discontinued . Acetylcholinesterase inhibitors stimulate muscarinic receptors across the tracheobronchial tree, causing excessive, tenaceous airway secretions, bronchospasm, and bradycardia. These secretions plug the endotracheal tube, complicate pulmonary toilet, and prolong mechanical ventilation. Furthermore, high-dose pyridostigmine can induce a cholinergic crisis (excessive acetylcholine causing depolarizing neuromuscular blockade and fasciculations), which is clinically indistinguishable from worsening myasthenic crisis. Pyridostigmine is reintroduced only at low doses when the patient is recovering and extubation is imminent.

Guillain-Barré Syndrome (GBS)

Guillain-Barré syndrome (GBS) is an acute, immune-mediated, post-infectious polyradiculoneuropathy. In Western nations, Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) accounts for 85 − 90 % 85-90\% 85 − 90% of cases, while Acute Motor Axonal Neuropathy (AMAN) and Acute Motor and Sensory Axonal Neuropathy (AMSAN) predominate in East Asia and Latin America. The Miller Fisher variant presents with the classic clinical triad of ataxia, ophthalmoplegia, and areflexia, driven by anti-GQ1b ganglioside antibodies.

Pathogenesis and Antecedent Triggers

GBS is driven by molecular mimicry. Antecedent infectious pathogens share lipooligosaccharide epitopes that mimic human gangliosides (e.g., GM1, GD1a, GQ1b) on peripheral nerve axons and Schwann cell myelin sheaths:

• Campylobacter jejuni (most common trigger, strongly associated with AMAN variants and severe axonal injury)
• Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Mycoplasma pneumoniae , Zika virus, and SARS-CoV-2
• Clinical Presentation and Autonomic Instability

GBS classically manifests as rapidly progressive, symmetrical ascending flaccid weakness starting in the lower extremities, accompanied by diminished or absent deep tendon reflexes ( hypo- or areflexia ) and distal paresthesias. Respiratory muscle involvement occurs in 25 − 30 % 25-30\% 25 − 30% of cases, requiring mechanical ventilation.

Autonomic Neuropathy (Dysautonomia) develops in up to 70 % 70\% 70% of critically ill GBS patients, representing a leading cause of sudden death in the ICU:

Extreme hemodynamic lability: Paroxysmal, severe hypertension alternating unpredictably with profound orthostatic hypotension.

Cardiac arrhythmias: Sustained sinus tachycardia, marked sinus bradycardia, second- or third-degree atrioventricular heart block, and asystole.

Gastrointestinal dysfunction: Severe paralytic ileus and acute urinary retention.

Continuous invasive arterial blood pressure monitoring and telemetry are mandatory. Clinicians must use ultra-short-acting, titratable vasoactive agents (e.g., esmolol for severe tachy-hypertension, phenylephrine or norepinephrine for hypotension) and avoid long-acting antihypertensives or aggressive fluid boluses.

Diagnostic Hallmark: Albuminocytologic Dissociation

Lumbar Puncture : Cerebrospinal fluid analysis reveals albuminocytologic dissociation —a markedly elevated CSF protein concentration ( > 45 mg/dL > 45\text{ mg/dL} > 45 mg/dL , frequently > 100 − 300 mg/dL > 100-300\text{ mg/dL} > 100 − 300 mg/dL ) accompanied by a normal CSF white blood cell count ( < 5 WBCs/ μ L < 5\text{ WBCs/}\mu\text{L} < 5 WBCs/ μ L ) .

Critical Diagnostic Caveat : CSF protein is completely normal in up to 50 % 50\% 50% of patients during the first 3 − 7 days 3-7\text{ days} 3 − 7 days of clinical weakness. A normal initial CSF protein does not exclude GBS; if clinical suspicion is high, the lumbar puncture should be repeated at 10 − 14 days 10-14\text{ days} 10 − 14 days .

Management and Contraindications

First-Line Immunotherapy : Either IVIG ( 0.4 g/kg/day × 5 days 0.4\text{ g/kg/day} \times 5\text{ days} 0.4 g/kg/day × 5 days ) or PLEX (4 to 5 plasma exchanges) administered within the first 2 − 4 weeks 2-4\text{ weeks} 2 − 4 weeks of onset. Combining IVIG and PLEX provides no clinical advantage and increases complications.

Corticosteroids are Ineffective : Multiple randomized multicenter clinical trials have demonstrated that systemic corticosteroids (oral or IV) do not accelerate recovery, do not improve functional mobility, and oral steroids may actually delay recovery. Corticosteroids are strictly not recommended for GBS.

Contraindication to Succinylcholine : Succinylcholine administration carries a high risk of lethal, refractory hyperkalemic cardiac arrest due to massive upregulation of extrajunctional acetylcholine receptors across denervated skeletal muscle. If intubation is required, use a nondepolarizing agent such as rocuronium (sugammadex is available for reversal).

ICU-Acquired Weakness: Critical Illness Myopathy vs. Polyneuropathy

ICU-Acquired Weakness (ICUAW) develops in 40 − 70 % 40-70\% 40 − 70% of patients with prolonged mechanical ventilation ( > 7 days > 7\text{ days} > 7 days ), severe sepsis, or septic shock. It is categorized into Critical Illness Myopathy (CIM) , Critical Illness Polyneuropathy (CIP) , or a combined Critical Illness Neuromyopathy (CINM) .

Diagnostic Domain Critical Illness Myopathy (CIM) Critical Illness Polyneuropathy (CIP)

Primary Pathology Non-necrotizing myopathy; selective loss of thick myosin filaments Distal axonal sensorimotor polyneuropathy; primary axonal degeneration

Sensory Examination Completely intact sensation Impaired sensation (stocking-glove loss of pain, vibration, touch)

Motor Weakness Flaccid quadriparesis (proximal and distal equally affected); facial weakness common Flaccid quadriparesis (distal > proximal); facial muscles typically spared

Deep Tendon Reflexes Decreased or preserved Uniformly diminished or completely absent

Serum Creatine Kinase Elevated early ( 2 − 5 × 2-5\times 2 − 5 × normal), normalizes in subacute phase Completely normal

Electrophysiology (NCS) Low CMAP amplitudes; Normal Sensory Nerve Action Potentials (SNAPs) Both CMAP AND SNAP amplitudes markedly reduced ; normal latencies

Direct Muscle Stimulation Muscle membrane unexcitable Muscle membrane excitable

Muscle Biopsy Selective loss of thick myosin filaments; intact architecture Denervation group atrophy; fiber-type grouping

Clinical Prognosis Favorable ; full recovery over weeks to months following illness resolution Guarded ; slow axonal regrowth ( 1 mm/day 1\text{ mm/day} 1 mm/day ); long-term severe disability

Clinical Risk Factors and Prevention

Major risk factors include prolonged sepsis/septic shock, multiorgan failure, hyperglycemia, systemic high-dose corticosteroids, and continuous infusions of non-depolarizing neuromuscular blocking agents (NMBAs). The synergistic combination of high-dose corticosteroids and continuous NMBAs is exceptionally myotoxic. Prevention relies on strict glycemic control ( 140 − 180 mg/dL 140-180\text{ mg/dL} 140 − 180 mg/dL ), early physical therapy and mobilization, daily spontaneous awakening trials (SAT), and minimizing sedative, steroid, and NMBA exposure.

Brain Death Determination: The 2023 Multisociety Guidelines

In 2023, the American Academy of Neurology (AAN), American Academy of Pediatrics (AAP), Child Neurology Society (CNS), and Society of Critical Care Medicine (SCCM) updated the consensus practice guideline for determination of brain death / death by neurologic criteria (BD/DNC) . Brain Death Determination Algorithm (2023 Update):

• [Step 1: Verify All Prerequisites]
• ├── Irreversible, catastrophic structural/anoxic etiology established via neuroimaging
• ├── Core temperature >= 36.0°C (96.8°F)
• ├── Hemodynamic stability: SBP >= 100 mmHg or MAP >= 75 mmHg
• ├── Absence of CNS depressants: >= 5 elimination half-lives or subtherapeutic drug levels
• ├── Absence of neuromuscular blockade: Train-of-four 4/4 brisk twitches
• └── Correction of severe metabolic, electrolyte, and acid-base derangements
• │
• [Step 2: Complete Clinical Examination]
• ├── Profound coma: Complete absence of motor/eye response to noxious stimulation

└── Absence of ALL brainstem reflexes:

• ├── Pupillary light reflex (bilateral fixed, midposition 4-6 mm or dilated)
• ├── Corneal reflex (bilateral absent)
• ├── Oculocephalic reflex (Doll's eyes absent)
• ├── Oculovestibular reflex (Cold calorics: >= 50 mL ice water, absent for >= 60s)
• ├── Gag reflex (bilateral absent)
• ├── Cough reflex (deep carina suctioning absent)
• └── Sucking, rooting, oculocardiac reflexes absent
• (Spinal reflexes & Lazarus sign DO NOT preclude determination)
• │
• [Step 3: Apnea Testing]
• ├── Pre-oxygenate FiO2 1.0 (baseline PaO2 >= 200 mmHg, PaCO2 35-45 mmHg)
• ├── Disconnect ventilator; continuous apneic O2 (6 L/min carinal catheter or CPAP 5-10 cmH2O)
• ├── Observe for 8-10 minutes for spontaneous respiratory effort
• └── Draw ABG: PaCO2 >= 60 mmHg AND >= 20 mmHg rise above baseline with pH < 7.30
• │
• ├── If successfully completed and positive ──> PATIENT IS DECLARED BRAIN DEAD
• └── If aborted (hypotension, desaturation) or unfeasible ──> PROCEED TO ANCILLARY TESTING
• │
• [Step 4: Ancillary Testing (When Apnea Test or Exam Incomplete)]
• ├── Digital Subtraction Angiography (DSA: absent cerebral blood flow)
• ├── Nuclear Medicine Scan (Tc-99m HMPAO: "empty light bulb" / "hot nose" sign)
• └── Transcranial Doppler (TCD: reverberating flow or systolic spikes in bilateral MCAs/basilar)
• Prerequisites for Determination

Before commencing clinical testing, all prerequisites must be rigorously satisfied:

Proximate Irreversible Etiology : Neuroimaging (CT or MRI) must clearly demonstrate catastrophic structural, vascular, or anoxic brain injury compatible with the permanent loss of all brain and brainstem function.

Exclusion of Central Nervous System Depressants : Clinicians must allow for a minimum of 5 elimination half-lives of any sedative, anesthetic, or analgesic agent (adjusted for acute renal failure, hepatic dysfunction, ECMO, or targeted temperature management). If drug levels can be measured (e.g., pentobarbital, phenobarbital, ethanol), levels must be documented below the therapeutic/detectable threshold.

Absence of Neuromuscular Blockade : Document intact peripheral neuromuscular transmission via a train-of-four peripheral nerve stimulator, demonstrating 4/4 brisk twitches .

Normothermia : Core body temperature must be ≥ 36.0 ∘ C \ge 36.0^\circ\text{C} ≥ 36. 0 ∘ C ( 96.8 ∘ F 96.8^\circ\text{F} 96. 8 ∘ F ) measured via esophageal, bladder, or rectal probe. Hypothermia impairs cranial nerve reflexes and slows drug metabolism.

Hemodynamic Stability : Systolic blood pressure must be maintained at ≥ 100 mmHg \ge 100\text{ mmHg} ≥ 100 mmHg or Mean Arterial Pressure ≥ 75 mmHg \ge 75\text{ mmHg} ≥ 75 mmHg . Vasopressors and fluid resuscitation are permitted and recommended to achieve stability.

Exclusion of Severe Metabolic Confounders : Correct severe electrolyte derangements, profound hypophosphatemia, and acute endocrine crises (e.g., severe myxedema coma or adrenal insufficiency).

Clinical Examination and Spinal Reflexes

Coma : Complete unarousability and absence of eye opening or purposeful motor response to deep noxious stimulation administered to the temporomandibular joints, supraorbital ridges, sternum, and all four extremities.

Brainstem Reflexes : Complete absence of pupillary light reflexes (bilateral fixed, midposition 4 − 6 mm 4-6\text{ mm} 4 − 6 mm or dilated), corneal reflexes, oculocephalic reflexes, oculovestibular reflexes (cold caloric: instillation of ≥ 50 mL \ge 50\text{ mL} ≥ 50 mL ice water into each canal with intact tympanic membranes, observing for ≥ 60 seconds \ge 60\text{ seconds} ≥ 60 seconds with a 5-minute interval between ears), gag reflex, and cough reflex.

Note

Spinal Reflexes Do Not Preclude Brain Death :

Motor movements generated entirely within the spinal cord or peripheral nerves persist in up to 50 % 50\% 50% of brain-dead patients. These include deep tendon reflexes, plantar flexion, abdominal reflexes, the triple flexion response (hip flexion, knee flexion, and ankle dorsiflexion upon plantar stimulation), and the Lazarus sign (complex bilateral arm flexion, elevation off the chest, touching the neck or chin, occasionally accompanied by trunk flexion, triggered by hypoxia or cervical neck flexion). In contrast, decerebrate (extensor) and decorticate (flexor) posturing originate from the brainstem/midbrain and STRICTLY PRECLUDE the diagnosis of brain death .

Standardized Apnea Testing Protocol

Pre-Test Optimization : Ensure core temp ≥ 36.0 ∘ C \ge 36.0^\circ\text{C} ≥ 36. 0 ∘ C , SBP ≥ 100 mmHg \text{SBP} \ge 100\text{ mmHg} SBP ≥ 100 mmHg , and euvolemia. Pre-oxygenate with 100 % FiO 2 100\%\ \text{FiO}_2 100% FiO 2 ​ for 10 − 15 minutes 10-15\text{ minutes} 10 − 15 minutes . Titrate mechanical ventilation to achieve normocapnia (baseline PaCO 2 35 − 45 mmHg \text{PaCO}_2\ 35-45\text{ mmHg} PaCO 2 ​ 35 − 45 mmHg ) and PaO 2 ≥ 200 mmHg \text{PaO}_2 \ge 200\text{ mmHg} PaO 2 ​ ≥ 200 mmHg . Obtain a baseline arterial blood gas.

Ventilator Disconnection and Continuous Oxygenation : Disconnect the mechanical ventilator. Deliver continuous oxygenation via an insufflation catheter delivering 100 % O 2 100\%\ \text{O}_2 100% O 2 ​ at 6 L/min 6\text{ L/min} 6 L/min positioned at the carina, OR attach a continuous positive airway pressure (CPAP) valve circuit set to 5 − 10 cmH 2 O 5-10\text{ cmH}_2\text{O} 5 − 10 cmH 2 ​ O on 100 % FiO 2 100\%\ \text{FiO}_2 100% FiO 2 ​ to maintain alveolar recruitment and prevent atelectatic hypoxemia.

Continuous Observation : Observe the patient closely for 8 − 10 minutes 8-10\text{ minutes} 8 − 10 minutes for any spontaneous respiratory effort (chest or abdominal excursions). In apneic patients, PaCO 2 \text{PaCO}_2 PaCO 2 ​ climbs by approximately 2 − 3 mmHg/minute 2-3\text{ mmHg/minute} 2 − 3 mmHg/minute .

Arterial Blood Gas Confirmation : Draw an arterial blood gas at 8 − 10 minutes 8-10\text{ minutes} 8 − 10 minutes and reconnect the patient to the ventilator.

Positive Apnea Test Criteria (Confirms Brain Death) :

Complete absence of spontaneous respiratory efforts throughout the test, AND

Post-test arterial PaCO 2 ≥ 60 mmHg \text{PaCO}_2 \ge 60\text{ mmHg} PaCO 2 ​ ≥ 60 mmHg AND a rise of at least ≥ 20 mmHg \ge 20\text{ mmHg} ≥ 20 mmHg above the pre-test baseline, AND

Arterial pH < 7.30 \text{pH} < 7.30 pH < 7.30 .

Abort Criteria : The apnea test must be terminated immediately, the patient reconnected to the ventilator, and an ABG drawn if:

Systolic blood pressure falls to ≤ 100 mmHg \le 100\text{ mmHg} ≤ 100 mmHg (or MAP ≤ 75 mmHg \le 75\text{ mmHg} ≤ 75 mmHg ) despite vasopressor titration.

Pulse oximetry SpO 2 \text{SpO}_2 SpO 2 ​ falls < 85 % < 85\% < 85% for > 30 seconds > 30\text{ seconds} > 30 seconds .

Sustained, life-threatening cardiac arrhythmias develop.

In adults, the 2023 guideline requires one complete examination and one apnea test (two examinations in children), performed by a qualified clinician. After hypoxic-ischemic brain injury, such as cardiac arrest, wait at least 24 hours before evaluation.

Ancillary (Confirmatory) Testing

Ancillary testing is not required when the clinical examination and apnea test are safely and definitively completed. Ancillary testing is mandatory only when:

The apnea test cannot be safely completed or must be aborted due to severe hypoxemia or hemodynamic instability.

Cranial nerve reflexes cannot be fully evaluated (e.g., extensive facial trauma, enucleation, severe chemosis).

Confounding pharmacological or metabolic conditions cannot be resolved.

Indeterminate baseline PaCO 2 \text{PaCO}_2 PaCO 2 ​ in chronic hypercapnic respiratory failure (e.g., severe COPD or obesity hypoventilation).

Validated Ancillary Modalities (Demonstrating Absence of Cerebral Blood Flow) :

Digital Subtraction Angiography (DSA) : The gold standard. Demonstrates complete bilateral absence of intracranial blood flow beyond the carotid siphon (internal carotid arteries) and foramen magnum (vertebral arteries).

Radionuclide Cerebral Perfusion Scintigraphy (SPECT Scan) : Technetium-99m labeled lipophilic agents (Tc-99m HMPAO or ECD) demonstrate complete absence of intracranial tracer uptake, yielding the pathognomonic "empty light bulb" or "hollow skull" sign , with preserved external carotid circulation producing the "hot nose" sign .

Transcranial Doppler Ultrasonography (TCD) : Demonstrates reverberating flow (biphasic oscillating flow) or small systolic spikes ( < 50 cm/s < 50\text{ cm/s} < 50 cm/s ) without diastolic flow in bilateral middle cerebral arteries and the basilar artery, confirmed across two examinations separated by ≥ 30 minutes \ge 30\text{ minutes} ≥ 30 minutes .